# Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

> **NCT03172598** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 61 (actual)

## Conditions studied

- Painful Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** MT-8554 low dose
- **DRUG:** MT-8554 middle dose
- **DRUG:** MT-8554 high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03172598
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-25
- **Primary completion:** 2018-08-08
- **Final completion:** 2018-08-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172598, "Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03172598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*